Adaptive Biotechnologies
Adaptive Biotechnologies Corporation, headquartered in the United States, is a pioneering leader in the biotechnology industry, specialising in immune-driven medicine. Founded in 2009, the company has made significant strides in harnessing the power of the adaptive immune system to develop innovative diagnostic and therapeutic solutions. With a focus on areas such as oncology and infectious diseases, Adaptive Biotechnologies offers unique products like the clonoSEQ® assay, which provides precise insights into the immune repertoire. This technology stands out for its ability to detect and quantify specific immune cells, enabling personalised treatment strategies. Recognised for its contributions to precision medicine, Adaptive Biotechnologies has established a strong market position, collaborating with major pharmaceutical companies and research institutions to advance the field of immunology.
DitchCarbon Score
How does Adaptive Biotechnologies's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Adaptive Biotechnologies's score of 20 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Adaptive Biotechnologies's reported carbon emissions
Adaptive Biotechnologies, headquartered in the US, currently does not have publicly available data regarding its carbon emissions, as there are no reported figures for emissions in kg CO2e. Additionally, there are no specified reduction targets or climate commitments outlined in their initiatives. This lack of data suggests that the company may still be in the early stages of formalising its climate strategy or reporting on its environmental impact. As the biotechnology industry increasingly prioritises sustainability, it will be essential for Adaptive Biotechnologies to establish clear emissions reduction goals and commitments to align with industry standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Adaptive Biotechnologies is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
